Type 2 Diabetes Management

Introduction to Type 2 Diabetes Management

• Type 2 diabetes management involves a comprehensive approach, including lifestyle modifications and pharmacologic therapy, as recommended by the American Diabetes Association 1, 2, 3

Initiation of Therapy

• For patients with HbA1c of 8.2%, consider initiating dual therapy immediately if the patient has symptoms or other risk factors, according to the American College of Physicians, as published in a study in 2016 4
• Dual therapy should be initiated when monotherapy with metformin at maximum tolerated dose does not achieve or maintain the HbA1c target over 3 months, or immediately when initial HbA1c is ≥9%, according to the American College of Physicians and the American Diabetes Association 4, 1

Treatment Options

• Metformin is the preferred first-line pharmacologic agent for type 2 diabetes management, according to the American College of Physicians and the American Diabetes Association 4, 1
• Alternative first-line options, such as α-glucosidase inhibitors and Sulfonylureas, can be considered if metformin is contraindicated or not tolerated, as suggested by the European Association for the Study of Diabetes 2
• Options for second agent include Sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors, with varying effects on weight and hypoglycemia risk, and additional benefits such as cardiovascular and renal protection 4
• Sulfonylureas are a cost-effective option for second-line therapy, with a cost of $12,757 per QALY gained, as reported by the Annals of Internal Medicine 5
• DPP-4 inhibitors are weight neutral with low hypoglycemia risk, as recommended by the American Diabetes Association 1
• GLP-1 receptor agonists promote weight loss, according to the American College of Physicians 4
• Basal insulin is particularly effective when HbA1c is significantly elevated, as suggested by the American Diabetes Association 1
• SGLT2 inhibitors can be added if HbA1c target is not achieved with metformin alone, providing cardiovascular and renal protection, as recommended by the American Diabetes Association 6
• Tirzepatide can be safely used in patients with type 2 diabetes, with a recommended starting dose of 2.5 mg once weekly and a maximum dose of 15 mg weekly, as suggested by the American Association of Clinical Endocrinologists and the American College of Endocrinology 7

Lifestyle Modifications

• Reduce refined carbohydrates and increase fiber intake, increase physical activity, and aim for weight loss if overweight/obese to reduce triglycerides, as recommended by the American Diabetes Association 3
• Adopt a Mediterranean diet pattern with emphasis on fiber-rich whole grains, reduced red meat consumption, and increased olive oil and nuts to address glycemic control and triglycerides, as recommended by the American Diabetes Association 2, 3
• Engage in at least 150 minutes per week of moderate-intensity aerobic activity, and include resistance training 2-3 times per week to improve insulin sensitivity and glycemic control, as recommended by the American Diabetes Association 2, 3
• Intensive lifestyle modifications, including dietary changes and physical activity, are recommended for patients with prediabetes, with a nutrition plan targeting 5-10% weight loss if overweight or obese, and a physical activity plan of at least 150 minutes of moderate-intensity exercise per week, as recommended by the American Academy of Pediatrics and supported by the American Diabetes Association 8, 2, 9, 10

Monitoring and Follow-up

• Short-term follow-up (3 months) should include HbA1c, fasting glucose, complete blood count, and iron studies (ferritin, iron saturation) to assess response to treatment, as recommended by the American Diabetes Association 2
• Regular monitoring should include lipid profile every 6 months until at goal, then annually, albumin/creatinine ratio annually, and comprehensive metabolic panel annually to assess progression or regression, as recommended by the American Diabetes Association 6
• Annual comprehensive assessment, including complete metabolic panel, lipid profile, and kidney function, is recommended, according to the American Diabetes Association 11, 12
• Initial follow-up should be at 3 months to assess HbA1c response, and if target is not achieved, consider increasing metformin dose or adding a second agent, as recommended by the American Diabetes Association 1

Cardiovascular and Renal Protection

• SGLT2 inhibitors are particularly beneficial in reducing progression of diabetic kidney disease, as indicated by the moderately increased albumin/creatinine ratio, as recommended by the American Diabetes Association 6
• Aggressive management of all modifiable risk factors is essential to reduce cardiovascular risk, given the combination of T2DM, dyslipidemia, and PCOS, as recommended by the American Diabetes Association 6
• A Mediterranean diet supplemented with olive oil and/or nuts reduces major CV events in patients with T2DM, as demonstrated by the European Heart Journal 6
• Bariatric surgery causes long-term weight loss and reduces DM and risk factor elevations, with effects superior to lifestyle and intensive medical management alone, as reported by the European Heart Journal 6
• Moderate-intensity statin is recommended, targeting LDL-C <2.6 mmol/L (<100 mg/dL) to address elevated LDL and overall cardiovascular risk, as recommended by the American Diabetes Association 6

HbA1c Targets

• The American Diabetes Association recommends individualizing HbA1c targets based on life expectancy and presence of comorbidities or complications, with targets ranging from 6.0-7.0% for patients with life expectancy >10-15 years to 8.0-9.0% for patients with life expectancy <5 years, as recommended by the American Diabetes Association 1
• The following table summarizes the recommended HbA1c targets based on life expectancy and comorbidities:

• Patients at high risk for hypoglycemia should not be treated to an HbA1c target <7.0%, considering patient medical history and risk factors, as recommended by the American Diabetes Association 13

Special Considerations

• Metformin may be considered for patients with BMI ≥35 kg/m², age <60 years, or women with a history of gestational diabetes, as recommended by the American Diabetes Association 11, 12
• When initiating metformin, start at a low dose of 500 mg daily and increase by 500 mg every 1-2 weeks, with a target dose of 2000 mg daily in divided doses, as recommended by the American Academy of Pediatrics and supported by the American Diabetes Association 8, 2, 9, 10
• Elderly patients should prioritize avoiding hypoglycemia over strict control, and patients with renal impairment should have medication dosing adjusted appropriately, as recommended by the American Academy of Pediatrics and supported by the American Diabetes Association 2, 14, 15